Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 178

1.

Opportunities to improve immune-based prevention of HPV-associated cancers.

Stern PL, Roden RB.

Papillomavirus Res. 2019 Jun;7:150-153. doi: 10.1016/j.pvr.2019.04.010. Epub 2019 Apr 11.

2.

Cancer stem cell mobilization and therapeutic targeting of the 5T4 oncofetal antigen.

Harrop R, O'Neill E, Stern PL.

Ther Adv Vaccines Immunother. 2019 Jan 25;7:2515135518821623. doi: 10.1177/2515135518821623. eCollection 2019. Review.

3.

The failure of radical treatments to cure cancer: can less deliver more?

Dalgleish AG, Stern PL.

Ther Adv Vaccines Immunother. 2018 Dec 20;6(5-6):69-76. doi: 10.1177/2515135518815393. eCollection 2018 Sep. Review.

4.

Opportunities and challenges for human papillomavirus vaccination in cancer.

Roden RBS, Stern PL.

Nat Rev Cancer. 2018 Apr;18(4):240-254. doi: 10.1038/nrc.2018.13. Epub 2018 Mar 2. Review.

5.

Human papillomavirus-driven immune deviation: challenge and novel opportunity for immunotherapy.

Smola S, Trimble C, Stern PL.

Ther Adv Vaccines. 2017 Jun;5(3):69-82. doi: 10.1177/2051013617717914. Epub 2017 Jul 5. Review.

6.

Is immunity in cancer the key to improving clinical outcome?: Report on the International Symposium on Immunotherapy, The Royal Society, London, UK, 12-13 May 2017.

Stern PL.

Ther Adv Vaccines. 2017 Jun;5(3):55-68. doi: 10.1177/2051013617720659. Epub 2017 Jul 20. No abstract available.

7.

Targeting the 5T4 oncofetal glycoprotein with an antibody drug conjugate (A1mcMMAF) improves survival in patient-derived xenograft models of acute lymphoblastic leukemia.

McGinn OJ, Krishnan S, Bourquin JP, Sapra P, Dempsey C, Saha V, Stern PL.

Haematologica. 2017 Jun;102(6):1075-1084. doi: 10.3324/haematol.2016.158485. Epub 2017 Mar 24.

8.

Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic.

Oguejiofor K, Galletta-Williams H, Dovedi SJ, Roberts DL, Stern PL, West CM.

Oncotarget. 2017 Feb 28;8(9):14416-14427. doi: 10.18632/oncotarget.14796.

9.

The changing face of vaccines and vaccination.

Stern PL.

Vaccine. 2016 Dec 20;34(52):6653-6654. doi: 10.1016/j.vaccine.2016.11.014. Epub 2016 Nov 17. No abstract available.

10.

5T4 oncofoetal antigen: an attractive target for immune intervention in cancer.

Stern PL, Harrop R.

Cancer Immunol Immunother. 2017 Apr;66(4):415-426. doi: 10.1007/s00262-016-1917-3. Epub 2016 Oct 18. Review.

PMID:
27757559
11.

A Subtype of Olfactory Bulb Interneurons Is Required for Odor Detection and Discrimination Behaviors.

Takahashi H, Ogawa Y, Yoshihara S, Asahina R, Kinoshita M, Kitano T, Kitsuki M, Tatsumi K, Okuda M, Tatsumi K, Wanaka A, Hirai H, Stern PL, Tsuboi A.

J Neurosci. 2016 Aug 3;36(31):8210-27. doi: 10.1523/JNEUROSCI.2783-15.2016.

12.

Stromal infiltration of CD8 T cells is associated with improved clinical outcome in HPV-positive oropharyngeal squamous carcinoma.

Oguejiofor K, Hall J, Slater C, Betts G, Hall G, Slevin N, Dovedi S, Stern PL, West CM.

Br J Cancer. 2015 Sep 15;113(6):886-93. doi: 10.1038/bjc.2015.277. Epub 2015 Aug 27.

13.

Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies.

Wang JW, Jagu S, Wu WH, Viscidi RP, Macgregor-Das A, Fogel JM, Kwak K, Daayana S, Kitchener H, Stern PL, Gravitt PE, Trimble CL, Roden RB.

Clin Vaccine Immunol. 2015 Jul;22(7):806-16. doi: 10.1128/CVI.00799-14. Epub 2015 May 13.

14.

Global gene expression in pseudomyxoma peritonei, with parallel development of two immortalized cell lines.

Roberts DL, O'Dwyer ST, Stern PL, Renehan AG.

Oncotarget. 2015 May 10;6(13):10786-800.

15.

Understanding and exploiting 5T4 oncofoetal glycoprotein expression.

Stern PL, Brazzatti J, Sawan S, McGinn OJ.

Semin Cancer Biol. 2014 Dec;29:13-20. doi: 10.1016/j.semcancer.2014.07.004. Epub 2014 Jul 25. Review.

PMID:
25066861
16.

Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.

Wang JW, Jagu S, Wang C, Kitchener HC, Daayana S, Stern PL, Pang S, Day PM, Huh WK, Roden RB.

PLoS One. 2014 Jul 7;9(7):e101576. doi: 10.1371/journal.pone.0101576. eCollection 2014.

17.

Editorial.

Ambrose CS, Bhattacharya J, Fox CB, McIntosh ED, Stern PL.

Ther Adv Vaccines. 2013 May;1(1):3-5. doi: 10.1177/2051013613486264. No abstract available.

18.

Investigation of radiosensitivity gene signatures in cancer cell lines.

Hall JS, Iype R, Senra J, Taylor J, Armenoult L, Oguejiofor K, Li Y, Stratford I, Stern PL, O'Connor MJ, Miller CJ, West CM.

PLoS One. 2014 Jan 22;9(1):e86329. doi: 10.1371/journal.pone.0086329. eCollection 2014.

19.

Comprehensive control of human papillomavirus infections and related diseases.

Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S; authors of ICO Monograph Comprehensive Control of HPV Infections and Related Diseases Vaccine Volume 30, Supplement 5, 2012.

Vaccine. 2013 Dec 31;31 Suppl 7:H1-31. doi: 10.1016/j.vaccine.2013.10.003.

PMID:
24332295
20.

Extended Middle East and North Africa: summary recommendations for the prevention of human papillomavirus infections and related cancers including cervical cancer.

Seoud M, Vaccarella S, El-Kak F, Sancho-Garnier H, Jumaan AO, Kim JJ, Garland SM, Stern PL, LaMontagne DS, Albero G, Bosch FX.

Vaccine. 2013 Dec 30;31 Suppl 6:G78-9. doi: 10.1016/j.vaccine.2012.11.078. No abstract available.

PMID:
24331823
21.

Comprehensive control of human papillomavirus infections and related diseases.

Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S; ICO Monograph 'Comprehensive Control of HPV Infections and Related Diseases' Vaccine Volume 30, Supplement 5, 2012.

Vaccine. 2013 Dec 30;31 Suppl 6:G1-31. doi: 10.1016/j.vaccine.2013.10.002. Review.

PMID:
24331817
22.

Comprehensive control of human papillomavirus infections and related diseases.

Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S; authors of the ICO Monograph ‘Comprehensive Control of HPV Infections and Related Diseases’ Vaccine Volume 30, Supplement 5, 2012.

Vaccine. 2013 Dec 29;31 Suppl 5:F1-31. doi: 10.1016/j.vaccine.2013.10.001. Review.

PMID:
24331745
23.

Comprehensive control of human papillomavirus infections and related diseases.

Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S; Authors of the ICO Monograph ‘Comprehensive Control of HPV Infections and Related Diseases’ Vaccine Volume 30, Supplement 5, 2012.

Vaccine. 2013 Nov 22;31 Suppl 8:I1-31. doi: 10.1016/j.vaccine.2013.07.026. Review.

24.

Poor prognosis associated with human papillomavirus α7 genotypes in cervical carcinoma cannot be explained by intrinsic radiosensitivity.

Hall JS, Iype R, Armenoult LS, Taylor J, Miller CJ, Davidson S, de Sanjose S, Bosch X, Stern PL, West CM.

Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):e223-9. doi: 10.1016/j.ijrobp.2012.11.030. Epub 2013 Jan 17.

PMID:
23332225
25.

Therapy of human papillomavirus-related disease.

Stern PL, van der Burg SH, Hampson IN, Broker TR, Fiander A, Lacey CJ, Kitchener HC, Einstein MH.

Vaccine. 2012 Nov 20;30 Suppl 5:F71-82. doi: 10.1016/j.vaccine.2012.05.091. Review.

26.

CXCL12 receptor preference, signal transduction, biological response and the expression of 5T4 oncofoetal glycoprotein.

McGinn OJ, Marinov G, Sawan S, Stern PL.

J Cell Sci. 2012 Nov 15;125(Pt 22):5467-78. doi: 10.1242/jcs.109488. Epub 2012 Sep 6.

27.

5T4 glycoprotein regulates the sensory input-dependent development of a specific subtype of newborn interneurons in the mouse olfactory bulb.

Yoshihara S, Takahashi H, Nishimura N, Naritsuka H, Shirao T, Hirai H, Yoshihara Y, Mori K, Stern PL, Tsuboi A.

J Neurosci. 2012 Feb 8;32(6):2217-26. doi: 10.1523/JNEUROSCI.5907-11.2012.

28.

5T4 oncofetal antigen is expressed in high risk of relapse childhood pre-B acute lymphoblastic leukemia and is associated with a more invasive and chemotactic phenotype.

Castro FV, McGinn OJ, Krishnan S, Marinov G, Li J, Rutkowski AJ, Elkord E, Burt DJ, Holland M, Vaghjiani R, Gallego A, Saha V, Stern PL.

Leukemia. 2012 Jul;26(7):1487-98. doi: 10.1038/leu.2012.18. Epub 2012 Jan 23.

29.

Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy.

Castro FV, Al-Muftah M, Mulryan K, Jiang HR, Drijfhout JW, Ali S, Rutkowski AJ, Kalaitsidou M, Gilham DE, Stern PL.

Cancer Immunol Immunother. 2012 Jul;61(7):1005-18. doi: 10.1007/s00262-011-1167-3. Epub 2011 Nov 30.

PMID:
22127365
30.

Clinical and immunological response to photodynamic therapy in the treatment of vulval intraepithelial neoplasia.

Daayana S, Winters U, Stern PL, Kitchener HC.

Photochem Photobiol Sci. 2011 May;10(5):802-9. doi: 10.1039/c0pp00344a. Epub 2011 Apr 14. Review.

PMID:
21494722
31.

For debate: that Australia should consider changing to the bivalent vaccine.

Stern PL.

Sex Health. 2010 Sep;7(3):238-41. No abstract available.

PMID:
21058497
32.

Circulating regulatory T cells in endometrial cancer: a role for age and menopausal status.

Sawan S, Burt DJ, Stern PL, Holland C, Elkord E.

Immunol Invest. 2011;40(1):62-75. doi: 10.3109/08820139.2010.513022. Epub 2010 Sep 1.

PMID:
20809698
33.

CXCR4 mediated chemotaxis is regulated by 5T4 oncofetal glycoprotein in mouse embryonic cells.

Southgate TD, McGinn OJ, Castro FV, Rutkowski AJ, Al-Muftah M, Marinov G, Smethurst GJ, Shaw D, Ward CM, Miller CJ, Stern PL.

PLoS One. 2010 Apr 1;5(4):e9982. doi: 10.1371/journal.pone.0009982.

34.

Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia.

Daayana S, Elkord E, Winters U, Pawlita M, Roden R, Stern PL, Kitchener HC.

Br J Cancer. 2010 Mar 30;102(7):1129-36. doi: 10.1038/sj.bjc.6605611. Epub 2010 Mar 16.

35.

Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma.

Ralph C, Elkord E, Burt DJ, O'Dwyer JF, Austin EB, Stern PL, Hawkins RE, Thistlethwaite FC.

Clin Cancer Res. 2010 Mar 1;16(5):1662-72. doi: 10.1158/1078-0432.CCR-09-2870. Epub 2010 Feb 23.

36.

5T4 as a target for immunotherapy in renal cell carcinoma.

Elkord E, Shablak A, Stern PL, Hawkins RE.

Expert Rev Anticancer Ther. 2009 Dec;9(12):1705-9. doi: 10.1586/era.09.152. No abstract available.

PMID:
19954280
37.

Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4).

Elkord E, Dangoor A, Burt DJ, Southgate TD, Daayana S, Harrop R, Drijfhout JW, Sherlock D, Hawkins RE, Stern PL.

Cancer Immunol Immunother. 2009 Oct;58(10):1657-67. doi: 10.1007/s00262-009-0674-y. Epub 2009 Feb 17.

PMID:
19221742
38.

Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity.

Karanam B, Gambhira R, Peng S, Jagu S, Kim DJ, Ketner GW, Stern PL, Adams RJ, Roden RB.

Vaccine. 2009 Feb 11;27(7):1040-9. doi: 10.1016/j.vaccine.2008.11.099. Epub 2008 Dec 16.

39.

Recommendations for cervical cancer prevention in Asia Pacific.

Garland SM, Cuzick J, Domingo EJ, Goldie SJ, Kim YT, Konno R, Parkin DM, Qiao YL, Sankaranarayanan R, Stern PL, Tay SK, Bosch FX.

Vaccine. 2008 Aug 19;26 Suppl 12:M89-98. doi: 10.1016/j.vaccine.2008.06.020.

PMID:
18945418
40.

An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases.

Elkord E, Dangoor A, Drury NL, Harrop R, Burt DJ, Drijfhout JW, Hamer C, Andrews D, Naylor S, Sherlock D, Hawkins RE, Stern PL.

J Immunother. 2008 Nov-Dec;31(9):820-9. doi: 10.1097/CJI.0b013e3181876ab3.

PMID:
18833005
41.

Clinical and immunologic results of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia.

Winters U, Daayana S, Lear JT, Tomlinson AE, Elkord E, Stern PL, Kitchener HC.

Clin Cancer Res. 2008 Aug 15;14(16):5292-9. doi: 10.1158/1078-0432.CCR-07-4760.

42.

Immunotherapy for gastrointestinal cancer: current status and strategies for improving efficacy.

Elkord E, Hawkins RE, Stern PL.

Expert Opin Biol Ther. 2008 Apr;8(4):385-95. doi: 10.1517/14712598.8.4.385 . Review.

PMID:
18352844
43.

Epithelial-mesenchymal transition events during human embryonic stem cell differentiation.

Eastham AM, Spencer H, Soncin F, Ritson S, Merry CL, Stern PL, Ward CM.

Cancer Res. 2007 Dec 1;67(23):11254-62.

44.

CD4+ T-cell recognition of human 5T4 oncofoetal antigen: implications for initial depletion of CD25+ T cells.

Elkord E, Burt DJ, Drijfhout JW, Hawkins RE, Stern PL.

Cancer Immunol Immunother. 2008 Jun;57(6):833-47. Epub 2007 Nov 15.

PMID:
18004564
45.

Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma.

Thistlethwaite FC, Elkord E, Griffiths RW, Burt DJ, Shablak AM, Campbell JD, Gilham DE, Austin EB, Stern PL, Hawkins RE.

Cancer Immunol Immunother. 2008 May;57(5):623-34. Epub 2007 Sep 27.

PMID:
17899077
46.

Novel vectors for homologous recombination strategies in mouse embryonic stem cells: an ES cell line expressing EGFP under control of the 5T4 promoter.

Perez-Campo FM, Spencer HL, Elder RH, Stern PL, Ward CM.

Exp Cell Res. 2007 Oct 1;313(16):3604-15. Epub 2007 Jul 28.

PMID:
17765223
47.

E-cadherin inhibits cell surface localization of the pro-migratory 5T4 oncofetal antigen in mouse embryonic stem cells.

Spencer HL, Eastham AM, Merry CL, Southgate TD, Perez-Campo F, Soncin F, Ritson S, Kemler R, Stern PL, Ward CM.

Mol Biol Cell. 2007 Aug;18(8):2838-51. Epub 2007 May 16.

48.

Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival.

Griffiths RW, Elkord E, Gilham DE, Ramani V, Clarke N, Stern PL, Hawkins RE.

Cancer Immunol Immunother. 2007 Nov;56(11):1743-53. Epub 2007 May 9.

PMID:
17487490
49.

A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma.

Shaw DM, Connolly NB, Patel PM, Kilany S, Hedlund G, Nordle O, Forsberg G, Zweit J, Stern PL, Hawkins RE.

Br J Cancer. 2007 Feb 26;96(4):567-74. Epub 2007 Feb 6.

50.

Supplemental Content

Loading ...
Support Center